CELLUS Group is a clinical-stage biomedical holding, focused on the development and commercialization of innovative cell therapies in the field of personalized medicine. Our mission is to fundamentally improve the treatment of invalidating diseases and injuries with unmet clinical needs, such as severe musculoskeletal damage and cancer.
CELLUS cell therapies are designed to restore the body’s native functions in a way that’s not possible with current traditional medicines. Our company developed an innovative and cost-effective cell purification and expansion method, to rapidly obtain large amounts of adult autologous clinical grade stem cells that are used to generate innovative cell products to heal musculoskeletal injuries faster and better. CELLUS also holds the exclusive licence of TapCells®, a personalized cellular immunotherapy for skin melanoma and prostate adenocarcinoma.
CELLUS Group comprehend CELLUS BIOMEDICA® as the holding company, where R&D, Quality Assurance System and IP is generated. CELLUS Group also incorporates three strategic divisions; CELLUS BIOFACTORY® (Advanced cellular products manufacturing), ONCOCELLUS® (Cancer Cellular Immunotherapy) and CELLUS CLINIC® (Regenerative rehabilitation and personalized cell therapy).